TIMP2
TIMP2 (tissue inhibitor of metalloproteinases 2)
Written by Aaron CuhaReviewed Sep 2026
Also known as: TIMP-2, Tissue inhibitor of metalloproteinases 2, Metalloproteinase inhibitor 2
A protein enriched in human umbilical cord plasma that restored hippocampal plasticity and memory in aged mice. It is already measured in people, as an acute kidney injury biomarker, but has never been given to one.
Overview
TIMP2 is a naturally occurring inhibitor of matrix metalloproteinases, present in everyone's blood. It became a longevity target through a 2017 Nature paper which asked whether human umbilical cord plasma, the earliest developmental stage of plasma available, contains plasticity-promoting factors. It does: cord plasma treatment improved hippocampal function and cognition in aged mice. Proteomic work identified TIMP2 as enriched in human cord plasma, in young mouse plasma and in young mouse hippocampi. Systemically administered TIMP2 appeared in the brain, increased synaptic plasticity and improved hippocampal-dependent cognition in aged mice, and depleting it abolished the benefit of cord plasma. The same work found that systemic TIMP2 is needed for spatial memory in young mice, and that treating brain slices with a TIMP2 antibody prevents long-term potentiation.
A 2023 Molecular Psychiatry paper extended this to neuronal TIMP2 specifically, linking it to hippocampus-dependent plasticity and to the complexity of the extracellular matrix around neurons.
TIMP2 has never been given to a human being for any indication. What exists in the human record is measurement, and a substantial amount of it, in a completely different clinical field. Urinary TIMP-2 multiplied by IGFBP7 is a validated biomarker of impending acute kidney injury: in a 2013 multicentre study, 522 critically ill adults were used for discovery and 728 for validation, where the combined marker gave an area under the curve of 0.80 for moderate to severe kidney injury within 12 hours and outperformed every previously described marker. That is human TIMP-2 data, it is good quality, and it is about kidneys rather than ageing.
Mechanism of action
In mice, systemically administered TIMP2 enters the brain and increases hippocampal synaptic plasticity and hippocampal-dependent cognition, and it is necessary for the cognitive benefit of human cord plasma. Blocking it with an antibody prevents long-term potentiation in brain slices, and neuronal TIMP2 regulates the complexity of the extracellular matrix around hippocampal neurons. In humans, the established biology is the canonical one: TIMP2 inhibits matrix metalloproteinases, and TIMP-2 together with IGFBP7 are inducers of G1 cell cycle arrest, which is the mechanism behind their use as kidney injury markers. Nothing links the mouse cognitive mechanism to a human outcome.
Human evidence
No human has received TIMP2 as a treatment. There is, however, a large human measurement literature: urinary TIMP-2 with IGFBP7 is a validated risk marker for acute kidney injury, studied in over a thousand critically ill adults. That is human TIMP2 data about kidneys, not about ageing or cognition.
- No administration study of any kind exists in people. No phase 1, no safety data, no pharmacokinetics, and no registered trial of TIMP2 as a therapeutic.
- Human biomarker data (Critical Care 2013): 522 critically ill adults in a discovery cohort spanning sepsis, shock, major surgery and trauma, with over 300 markers screened; 728 critically ill adults in the Sapphire validation cohort, of whom 14 percent developed moderate to severe acute kidney injury. Urinary TIMP-2 multiplied by IGFBP7 achieved an area under the curve of 0.80, and improved risk stratification when added to a nine-variable clinical model.
- The human source material for the mouse experiments is human umbilical cord plasma, which is a human biological product, but the experiments themselves are in aged mice.
What this does not tell you: The kidney biomarker literature tells you that TIMP-2 can be measured reliably in people and that it rises in a specific pathological state. It tells you nothing about whether giving TIMP2 to an older person would do anything to memory, and nothing about whether it would be safe. A matrix metalloproteinase inhibitor administered systemically has obvious questions attached, since metalloproteinase activity is involved in tissue remodelling, wound healing and tumour biology, and none of those questions has been asked in a human.
Reading the research record
TIMP2 is a good illustration of the difference between a factor with a mechanism and a factor with a drug programme. The 2017 Nature paper did the hard part properly: it identified a specific protein, showed it was necessary for the effect by depleting it, showed it was sufficient by administering it, and showed it reaches the brain. That is a stronger causal chain than most young-blood factors have. What has not happened in the nine years since is a human trial, and the registry has none.
One reason may be that TIMP2 is an endogenous human protein with a long-established role in matrix biology, which cuts both ways commercially: it is not novel chemical matter, and its known function means a systemic dose would be doing more than acting on the hippocampus. Another is that the intended population, cognitively ageing adults, requires large and long trials with endpoints that have defeated much better funded programmes.
The kidney biomarker use is a genuinely separate literature that happens to share a molecule, and it is included here so readers searching for TIMP-2 human data find the real answer rather than an assumption. It does not support any ageing claim.
The evidence, charted
Fig. 1 · evidence composition
1of 4 citations (25%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2011 to 2023, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2017
Human umbilical cord plasma proteins revitalize hippocampal function in aged mice
Mouse. Human umbilical cord plasma improved hippocampal function and cognition in aged mice. TIMP2, enriched in cord plasma, young mouse plasma and young mouse hippocampi, appeared in the brain after systemic administration and increased synaptic plasticity and hippocampal-dependent cognition in aged mice. Depleting TIMP2 removed the benefit of cord plasma. NIH funded with non-US government and non-PHS support.
Nature - Animal2023
Neuronal TIMP2 regulates hippocampus-dependent plasticity and extracellular matrix complexity
Mouse. Neuronal TIMP2 regulates hippocampus-dependent plasticity and the complexity of the extracellular matrix, extending the systemic finding to a cell-type-specific mechanism. NIH funded.
Molecular Psychiatry - Human2013
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
Human, and the largest body of TIMP-2 data in people, though it is not about ageing. Two multicentre observational studies in critically ill adults: 522 in discovery across sepsis, shock, major surgery and trauma cohorts with over 300 markers examined, and 728 in the Sapphire validation cohort. Urinary TIMP-2 combined with IGFBP7 gave an area under the curve of 0.80 for moderate to severe acute kidney injury within 12 hours, significantly better than all previously described markers (p < 0.002), none of which exceeded 0.72.
Critical Care - Animal2011
The ageing systemic milieu negatively regulates neurogenesis and cognitive function
Mouse. The parabiosis work establishing that blood-borne factors regulate adult neurogenesis in an age-dependent way, which is the framework the cord plasma and TIMP2 work sits inside.
Nature
Frequently asked questions
Has TIMP2 been given to a person?
No. There is no administration study of TIMP2 in humans for any indication and no registered trial. Everything about its cognitive effects comes from aged mice.
What did TIMP2 do in mice?
Systemically administered TIMP2 appeared in the brain, increased synaptic plasticity and improved hippocampal-dependent cognition in aged mice. It was also necessary for the cognitive benefit of human umbilical cord plasma, since depleting it removed that benefit, and blocking it with an antibody prevented long-term potentiation in brain slices.
Why do some labs measure TIMP-2 in people then?
For a completely different purpose. Urinary TIMP-2 combined with IGFBP7 is a validated risk marker for acute kidney injury, validated in 728 critically ill adults with an area under the curve of 0.80. That is a diagnostic test, not a treatment, and it has nothing to do with ageing.